News and Trends 6 Jan 2020 BioNTech’s RNA-Boosted CAR T-Cell Therapy Shrinks Tumors in Mice A CAR T-cell therapy amplified by RNA technology, developed by BioNTech, has shown preclinical potential for tackling solid tumors, which are hard to treat with current CAR T-cell therapies. In a study published in Science, the CAR T-cell and RNA combination therapy suppressed tumors in mice implanted with human ovarian cancer for longer than regular […] January 6, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2019 German Startup Raises €4M Seed Round to Make Dairy Cheese Without Milk Berlin-based startup Legendairy Foods has raised €4M to develop cheese and other dairy products that have the same composition as milk but are not derived from animals. The fundraising was co-led by food tech investor Agronomics and M Ventures, the corporate venture capital arm of Merck. CPT Capital, an investor in alternative proteins, […] December 20, 2019 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2019 Update: Cancer Immunotherapy Biotech Files for Insolvency Update (06/12/2019): Following the phase III failure of its immunotherapy drug for colorectal cancer in the summer, the German company Mologen has filed for insolvency. Published 06/08/2019 A DNA immunotherapy drug developed by the German company Mologen has failed to improve the survival of patients with colorectal cancer in a phase III trial. The phase […] December 6, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 5 Dec 2019 German Biotech Raises €7M Series A to Treat Acute Heart Failure 4TEEN4 Pharmaceuticals has raised a Series A round of €6.9M to fuel the development of a first-in-class antibody drug that could reduce mortality in acute heart failure. The round was led by Brandenburg Kapital, a subsidiary of the German investment bank Investitionsbank des Landes Brandenburg. Other investors in the round, including business angels and private […] December 5, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 28 Nov 2019 German Biotech to Develop Next-Generation Gene Therapy for Blindness The German biotech ViGeneron has raised an undisclosed sum in a Series A round to fund the development of an ophthalmic gene therapy that could deliver bigger DNA sequences into a wider range of cells than current technology. The round was led by two Chinese investors, the VC firm Sequoia Capital China and the pharma […] November 28, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 7 Nov 2019 €51M Nasdaq IPO Will Fund Centogene’s Rare Disease Diagnostics The German company Centogene has raised €50.6M ($56M) in an IPO on the Nasdaq Stock Exchange to fund the development of diagnostics technology that could improve the treatment of rare diseases. The fundraise fell under Centogene’s target value of €54M ($60M). A part of the proceeds will fuel the development of biomarkers that Centogene will […] November 7, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 4 Nov 2019 Top 10 Biotech Companies Leaving a Mark in Munich These are the top 10 biotech companies in Munich, one of the hottest hubs for the biotechnology industry. One of the largest cities in Germany, Munich is a hub for science and technology. Biotechnology is one of its many strengths, supported by strong academic research at the city’s two top universities: Ludwig Maximilian University and […] November 4, 2019 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2019 German Alzheimer’s Drug Backed with €43M After Biogen’s Surprise Turnaround The German company Vivoryon Therapeutics has raised €43M on Euronext Amsterdam to fund a phase IIb trial of a drug that could slow the progression of Alzheimer’s disease by blocking toxic forms of the protein amyloid-beta. Vivoryon Therapeutics, previously known as Probiodrug, raised the money using a rights offering and a private placement on Euronext […] October 24, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 10 Oct 2019 Update: BioNTech Files for €141M Nasdaq IPO BioNTech’s Nasdaq IPO has raised €141M ($155M), a lower sum than it initially anticipated. The timing of the IPO means it has likely been impacted by adverse market conditions, which are due to factors such as global manufacturing slowdowns and escalations in US and Chinese trade disputes. This same market volatility led several companies such […] October 10, 2019 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 25 Sep 2019 German Biotech Will Develop Carbohydrate-Targeting Cancer Treatments The German startup Tacalyx has raised €7M in a seed round to fund the preclinical development of first-in-class carbohydrate-targeting antibody drugs for the treatment of cancer. The round was co-led by the Germany-based Boehringer Ingelheim Venture Fund and the French VC firm Kurma Partners. Tacalyx will use the money to generate a lead candidate antibody […] September 25, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 11 Sep 2019 Grünenthal to Pay up to €900M for Chronic Low Back Pain Cell Therapy The German pharmaceutical company Grünenthal has licensed a donor cell therapy for chronic low back pain from the Australian biotech Mesoblast in a deal that could be worth over €900M. Under the terms of the deal, Grünenthal will gain exclusive rights to commercialize Mesoblast’s cell therapy for chronic low back pain in Europe and Latin […] September 11, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 28 Aug 2019 Celgene and Immatics Sign Deal Worth Over €1.35B to Develop Cancer Immunotherapies The US company Celgene has obtained options to three cancer immunotherapy programs from the German biotech Immatics in a deal worth more than €1.35B ($1.5B). Immatics is to receive an upfront payment of €67.5M ($75M), along with up to €455M ($505M) in developmental milestones and royalties for each immunotherapy program. In each program, Immatics will […] August 28, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email